Axon Enterprise (NASDAQ:AXON) CRO Sells $621,000.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise Stock Down 3.1%

NASDAQ:AXON traded down $15.06 on Monday, hitting $471.06. 941,797 shares of the company’s stock were exchanged, compared to its average volume of 1,098,205. The firm has a 50-day moving average price of $408.04 and a 200-day moving average price of $491.56. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The company has a market cap of $37.97 billion, a P/E ratio of 189.18, a price-to-earnings-growth ratio of 8.84 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. During the same period in the previous year, the firm posted $1.47 EPS. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. As a group, analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on AXON shares. Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citizens Jmp reduced their price target on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a report on Thursday, May 7th. Barclays reduced their price target on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, The Goldman Sachs Group set a $535.00 price target on Axon Enterprise in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after buying an additional 53,060 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Axon Enterprise by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after buying an additional 35,544 shares during the period. Baillie Gifford & Co. boosted its holdings in shares of Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after buying an additional 1,516,099 shares during the period. Sands Capital Management LLC boosted its holdings in shares of Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after buying an additional 167,095 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares during the period. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.